Meanwhile, Tango tries again in PRMT5.

AstraZeneca bags three of the month’s four oncology approvals.

But with Brukinsa and degraders looming, will fixed dosing make the difference?

Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.

First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.

NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.

AstraZeneca celebrates success in the Echo trial in mantle cell lymphoma, but watch out for BeiGene.

A look at big oncology deals since 2016 finds outright success stories hard to come by. 

Imbruvica faces challenges on multiple fronts.